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In this issue of Cancer Cell, Ahmed and coworkers identify SIK2 as a centrosome kinase and show that it
controls the localization of the centriole linker protein C-Nap1. Interference with SIK2 function results in
loss of normal mitotic spindle function and increased sensitivity to antitumor drugs.Cancer is a problem largely owing to
shifting tumor cell phenotypic heteroge-
neity due to intrinsic genomic instability
(Schvartzman et al., 2010). Tumor pro-
gression is a consequence of selection of
cancer cells with properties that confer
growth advantage, invasion, dispersal
along vascular or lymphatic routes, resi-
dence at distant metastatic sites, and
resistance to therapeutic challenge (Wein-
berg, 2008). Current cancer treatments, in
addition to surgical intervention, include
therapies that widely employ antimitotic
drugs and/or genotoxic modalities to
reduce tumor burden. Because these
treatments are often not completely effec-
tive, re-emergence froma small number of
surviving cells results in tumor recurrence
with an overall decrease in treatment
sensitivity and poor clinical outcome. For
this reason, strategies to discover novel
synergistic therapies directed against
manifold disparate tumor cell targets to
increase treatment efficacy are a high
priority.
In order to identify candidate genes
required for G2 and G2/M progression
as potential new cancer therapeutic
targets, Ahmed et al., (2010) employed
a reverse genetic screen using pools of
siRNA in combination with automated
high-throughput analysis of time-lapse
live cell imaging and measurement of
single-cell DNA content. Their strategy
was validated when the screen revealed
several known cell-cycle regulators,
including Cyclin Dependent Kinase1,
Polo Kinase, and Aurora Kinase B, that
upon knockdown induced a ‘‘ploidy’’ shift
through either delay or arrest of G2/M. Six
novel genes were also identified and
authenticated as targets that delayed
mitotic progression. The authors selected
one—the ‘‘Salt Inducible Kinase2’’(SIK2)—for detailed investigation, be-
cause while SIK2 was known to function
in regulation of cellular metabolism, its
potential role in cell-cycle regulation had
not been previously documented. Further
validation of SIK2 in control of mitosis
revealed that loss-of-function resulted
in a dramatic increase in the time to com-
plete mitotic progression (two to three
times as long as normal). Importantly,
many of the SIK2-depleted cells also
exhibited mitotic catastrophe, cell death,
or failure to execute cytokinesis, resulting
in polyploidy.
To address the clinical significance of
SIK2 in cancer, the authors used apopula-
tion-based study of 229 ovarian cancer
patients together with gene microarray
and quantitative PCR analyses to assess
the relationship between clinical outcome
and SIK2 expression levels. They found
that elevated expression of SIK2 signifi-
cantly correlated with poor outcome
following taxane-based chemotherapy
for ovarian cancers. Also, a second study
comparing paclitaxel versus carboplatin
resistant and responsive ovarian cancers
confirmed that the SIK2 expression was
higher in paclitaxel-resistant compared
to paclitaxel-sensitive cancers, while
there was no significant difference for
carboplatin. Thus, SIK2 expression
showed a greater influence on outcomes
following treatment with mitotic inhibitors
than for genotoxic agents.
Next, to elucidate the mechanism
underlying the link between SIK2, mitotic
function, and taxane sensitivity, the
authors explored SIK2 localization in cul-
tured cells. Surprisingly, SIK2 showed a
distinct juxtanuclear colocalization with
g-tubulin that was not sensitive to noco-
dazole-induced microtubule depolymer-
ization. Colocalization was seen in 70%Cancer Cell 1of interphase cells and at the spindle
poles in virtually all mitotic cells. Addition-
ally, SIK2 localization was mimicked by
recombinant GFP-SIK2 and was sensitive
to SIK2 knockdown. Taken together,
these observations demonstrate that
SIK2 is an intrinsic component of the
centrosome, the cell’s major microtubule
organizing organelle, and they beg the
question of just exactly what is SIK2 doing
at the ‘‘cell center.’’
In addition to its fundamental role in
microtubule organization, the centrosome
provides an important structural context
for coordinating cell-cycle regulation
(Doxsey, 2001; Mikule et al., 2007; Sluder
and Hinchcliffe, 2000). Centrosomes
consist of three fundamental structural
parts, including a core structure consist-
ing of a pair of microtubule-based centri-
oles that serve as a centrosomeorganizer;
a protein lattice or matrix that surrounds
the centrioles called pericentriolar mate-
rial (PCM), which serves as a framework
to anchor microtubule nucleation sites;
and finally, g-tubulin complexes that are
responsible for the nucleation of microtu-
bules. Throughout a normal cell cycle,
centrioles occur in pairs—cells contain
either one or two pair of centrioles de-
pending on the cell-cycle stage, with a
pair of centrioles residing at each mitotic
spindle pole. At the completion of mitosis
and cell division, each daughter cell
inherits one centrosome containing a pair
of centrioles. During most of this process,
centriole pairs, and newly doubled centro-
somes remain tethered to one another by
linking fibers, consisting in part of the
coiled-coil protein, C-Nap1 (Bahe et al.,
2005; Fry et al., 1998). Unraveling or disso-
lution of the linking fibers allows splitting of
centriole pairs and separation of newly
doubled centrosomes.8, August 17, 2010 ª2010 Elsevier Inc. 99
Figure 1. SIK2 Regulates C-Nap1-Mediated Cohesion of Doubled Centrosomes
Centrosomes double once in each cell cycle through the duplication of centrioles (green cylinders) and
acquisition of additional pericentriolar material (red cloud). Centriole pairs and doubled centrosomes
remain connected through fibers, which are composed in part of C-Nap1. Late in G2 phase of the cell
cycle, SIK1 phosphorylates C-Nap1, which solate or detach to allow centrosome separation and bipolar
mitotic spindle formation. Inhibition of SIK2 function results in failure of centrosome separation, monopolar
spindle formation, and ultimately leads to polyploidization and increased antitumor drug sensitivity.
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workers overexpressed SIK2 in cultured
cells, they saw precocious centrosome
splitting reminiscent of the separation of
newlydoubledcentrosomes inG2/Mcells.
Furthermore, searching the genome data-
base revealedaputativeSIK2serinephos-
phorylation consensus in the C-terminal
domain of the centrosome linker protein
C-Nap1, which they then demonstrated
served as a target for in vitro phosphoryla-
tion using recombinant SIK2. Coprecipita-
tion and refined colocalization confirmed
a close link between SIK2 and C-Nap1.
These results and other confirmatory
studies highly implicate C-NAP1 as a
physiological centrosome target of SIK2.100 Cancer Cell 18, August 17, 2010 ª2010 ETo further examine the role of SIK2 in
mitotic progression and to explain the
increased sensitivity of paclitaxel as an
antitumor treatment, Ahmed and co-
workers re-examined cells in which SIK2
was ablated using siRNA for centrosome
defects. These experiments showed
failure of centrosome separation and
decreased frequency of bipolar mitotic
spindles, which could be rescued by
re-expression of recombinant SIK2. By
interfering with the centrosome targeting
of the known SIK2 inhibitor, protein kinase
A (PKA), Ahmed et al. also demonstrated
a potential regulatory role for PKA in the
timing of centrosome separation in late
G2 through control of SIK2.lsevier Inc.Taken together, these experiments
implicate SIK2 in the control of prometa-
phase separation of centrosomes giving
rise to bipolar mitotic spindle organization
through phosphorylation of C-NAP1 (see
Figure 1). Furthermore, they suggest that
monoploar spindle formation, delayed
mitosis, and failure of cytokinesis in SIK2
defective cells can lead to increased
sensitization to taxane-based anticancer
treatments. The studies by Ahmed and
coworkers are exciting because they
validate a rationale for discovery of previ-
ously unrecognized cell-cycle control
processes and they also provide insight
into novel avenues for the development
of cancer therapeutics that, when used
in combination with established treat-
ments, may act synergistically to extend
disease free survival and good clinical
outcomes.
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